October 17, 2024 11:12 AM EDT
News Briefing

Vi­a­tris, Lex­i­con ink li­cens­ing deal; Capri­cor’s $75M of­fer­ing

ENDPOINTS

Plus, news about Kezar Life Sci­ences and Con­cen­tra Bio­sciences:

Vi­a­tris, Lex­i­con Phar­ma­ceu­ti­cals sign li­cens­ing deal for car­dio drug: Per the agree­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times